Pfizer will buy 8.1% of the capital of vaccine company Valneva By Reuters


© Reuters. FILE PICTURE: Man walks past Pfizer logo amid coronavirus pandemic (COVID-19) in Manhattan, New York, New York, USA, April 1, 2021. REUTERS / Carlo Allegri


PARIS (Reuters) – French specialty vaccine company Valneva and US healthcare giant Pfizer NYSE 🙂 said it has entered into a shareholding agreement under which Pfizer will invest 90.5 million euros ($ 95.24 million) in Valneva, representing 8.1% of its capital.

The deal comes through a reserved capital increase to further support Lyme’s strategic partnership between the two companies, the statement added.

(1 $ = 0.9502 euros)

Related Posts

Leave a Reply

Your email address will not be published.